Literature DB >> 11205270

The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma.

K N Syrigos1, A Charalambopoulos, K Pliarchopoulou, N Varsamidakis, A Machairas, D Mandrekas.   

Abstract

BACKGROUND: The tumors of the gastrointestinal system have been associated with various immune disorders. The goal of this study was to correlate the presence of the anti-dsDNA autoantibodies in the serum of patients with colorectal adenocarcinoma suffering from the prognosis of their disease. PATIENTS AND METHODS: We investigated 55 patients with colorectal adenocarcinoma, 26 patients with benign surgical disease and 40 healthy volunteers for the presence of anti-dsDNA autoantibodies pre-operatively and one month post-operatively, with an ELISA technique.
RESULTS: The difference of prevalence of anti-dsDNA antibodies between the group of cancer patients and the two control groups was statistically significant (p < 0.001). After a 3-year follow-up, the difference of incidence of the recurrences between the positive and the negative group for anti-dsDNA autoantibodies of the CA patients was statistically significant (P < 0.01).
CONCLUSION: The presence of anti-dsDNA autoantibodies in patients with colorectal cancer indicated a better outcome of the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205270

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

2.  Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus.

Authors:  M M Freemer; T E King; L A Criswell
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

3.  Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity.

Authors:  Diana A Alvarez Arias; Hye-Jung Kim; Penghui Zhou; Tobias A W Holderried; Xuan Wang; Glenn Dranoff; Harvey Cantor
Journal:  Cancer Immunol Res       Date:  2013-12-31       Impact factor: 11.151

4.  IgG deposits can be detected in cell nuclei of patients with both lupus erythematosus and malignancy.

Authors:  Ingrid Böhm
Journal:  Clin Rheumatol       Date:  2007-03-16       Impact factor: 2.980

5.  An Unusual Mimicker of Systemic Lupus Erythematosus: A Case Report.

Authors:  Aloice O Aluoch; Mathew Farbman; Heather Gladue
Journal:  Open Rheumatol J       Date:  2015-06-12

6.  The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.

Authors:  Jinyan Guo; Zhigang Ren; Jianhao Li; Tianfang Li; Shengyun Liu; Zujiang Yu
Journal:  Arthritis Res Ther       Date:  2020-06-26       Impact factor: 5.156

Review 7.  The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

Review 8.  Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases.

Authors:  Kalliopi Klavdianou; Konstantinos Melissaropoulos; Alexandra Filippopoulou; Dimitrios Daoussis
Journal:  Mediterr J Rheumatol       Date:  2021-09-30

9.  Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

Review 10.  Immunotherapy to treat malignancy in patients with pre-existing autoimmunity.

Authors:  Patrick Boland; Anna C Pavlick; Jeffrey Weber; Sabina Sandigursky
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.